Cancer is among diseases associated with widespread deaths around the globe. Thus, there has been an increase in the demand for information relating to its treatment and management. The information is a result of intensive researches conducted by scientists in the biomedical field. The specific branch of medicine dealing with the prevention diagnosis and treatment of cancer is known as Oncology. In the fight against cancer, it has become apparent that understanding the influence of other fields in prevention and treatment is of the essence. One journal that has significantly been involved in disseminating information relating to Oncology is Oncotarget.
Oncotarget is a multidisciplinary traditional medical journal covering all aspects of oncology. The peer-reviewed journal moved from a weekly publication to being published two times in a week owing to increased demand. The demand was attributed to its impact and quality. Also, Oncotarget’s insightful, constructive, and multi peer-review has enabled authors to publish essential research papers. The journal accepts publications from different authors which are reviewed by a highly qualified and experienced who facilitate timely publishing of the papers. In essence, it has endeavored to explore different therapies, management approaches, and their impact on patients.
The online journal operates on a free-access basis. An issue may be printed if there is a particular demand. Oncotarget has been instrumental in the increased spread of significant scientific information, in particular, in the medical field. It has provided an ample platform to foster the application of basic and clinical science in the search for preventive and curative measures to deal with cancer. The journal introduced other sections covering Cell Biology, Neuroscience, Endocrinology, and Pharmacology among others. The idea has further enhanced Oncotarget’s role through linking of different biomedical fields. The integration of this knowledge is an essential step towards the fight against cancer.
In the modern world, cases of diseases are on the rise owing to the changes in lifestyle which is triggered by the dynamic and unstable state of the economy. Therefore, health professionals are spending sleepless nights to ensure that the whole world is posted about every ailment and the best ways to curb. Thanks to the advancements in technology, today, sharing of such crucial information have turned quite comfortable as one can access the information regardless of his or her locality through the internet.In the recent past, Oncotarget is among the few platforms in the healthcare industry who have been working tirelessly to provide the world with the necessary information. Oncotarget is popularly known for publishing official medical reports. The medical journal came in place in 2010 and primarily focused on oncology, a category of medicine that deals with the medical examination and treatment of cancer.
Oncotarget understands how crucial the cancer topic is to the world that is directly or indirectly affected by the ailment. Therefore, the journal dedicates its presence to keep the world posted with the findings and tests related to cancer.However, in the recent past, Oncotarget felt the need to broaden its duties. Today, Oncotarget also features publications from non-oncological conditions such as microbiology, neuroscience, cardiology, and pharmacology among many other crucial fields. Oncotarget is an open-source journal and releases books on a weekly basis. The journal’s publications are usually featured on various social platforms such as Facebook, Twitter, YouTube, Google, and Linked.
The healthcare field is a bit complex, particularly for those with little knowledge about the area. However, Oncotarget has made sure that all the publications are delivered in the simplest way possible. Interested parties can quickly and easily access the journal’s papers hence receiving the relayed info. Since establishment, Oncotarget has continued to provide its readers with proven facts and actual information related to their daily happenings. However, both Dr. Andrei V. Gudkov and Mikhail Blagosklonny play a super role of ensuring accuracy on every posting. Both Andrei and Mikhail act as a journal’s chief editors. The two chief editors also lecture at Rosewell Park Institute. Recently, Oncotarget researched on the effects of E-cigarettes on human teeth and published it to reach the millions of readers who use e-cigarettes as the new trend.
Cancer is a serious disease that ends lives much too soon all around the world. With such a terrible disease, it’s no surprise that measures are being taken to help treat it more efficiently. Many of us, especially Eric Lefkofsky, wonder how we can better diagnose cancer and find the best treatments available. According to this recent article regarding the health field and cancer itself, Eric Lefkofsky believes that critical data is missing from today’s medical research systems.
Eric Lefkofsky founder and CEO of Tempus, which is a startup that aims to provide more successful accuracy in treating cancer by supplying data for both genomics and therapeutic data. This would allow doctors to fine-tune cancer treatments and provide better overall care for their patients. With Tempus, there is a free flow of information between researchers, clinicians, and others.
After his wife was diagnosed with breast cancer, Lefkofsky felt personally inclined to start and develop Tempus. The central idea behind Tempus is to build a technology layer above existing electronic medical records and pathology systems to aggregate the data and receive an edited version back with patterns of treatments and results, showing which have been proven to successful.
In addition to Tempus, Eric Lefkofsky is known for many other notable works. He is the co-founder of Groupon, which is a global e-commerce marketplace used by many around the world. In 2006, he opened up the Lefkofsky Family Foundation, which is a private charitable foundation.
He opened this foundation up with his wife, Liz, in order to enhance the lives in the communities it serves. With Tempus just being a small glimpse of his work in the healthcare industry, Lefkofsky also serves as a Trustee of Lurie Children’s Hospital of Chicago. He also has a passion for the arts, being a Trustee at the Art Institute of Chicago and Chairman of the Board of Trustee’s of Chicago’s Steppenwolf Theatre Company.
for more info: chicagoinno.streetwise.co/2016/07/22/eric-lefkofskys-next-move-curing-cancer-at-tempus/